Phoenix DX (previously LIG Biowise) is an innovative medical diagnostics company developing an ultra-rapid, point-of-care (POC) diagnostic device for infectious diseases. Its platform technology combines nucleic acid extraction, amplification, and detection into a single step, resulting in faster diagnostic turn around, lower costs and higher precision. Initially targeting diagnostics for upper respiratory tract infections (URTIs), Phoenix DX is set to transform antibiotic prescribing practices and tackle antimicrobial resistance from its base in Manchester, UK.